25763772|t|DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis
25763772|a|Pseudomonas aeruginosa (Pa) infection in cystic fibrosis (CF) patients is associated with worse long-term pulmonary disease and shorter survival, and chronic Pa infection (CPA) is associated with reduced lung function, faster rate of lung decline, increased rates of exacerbations and shorter survival. By using exome sequencing and extreme phenotype design, it was recently shown that isoforms of dynactin 4 (DCTN4) may influence Pa infection in CF, leading to worse respiratory disease. The purpose of this study was to investigate the role of DCTN4 missense variants on Pa infection incidence, age at first Pa infection and chronic Pa infection incidence in a cohort of adult CF patients from a single centre. Polymerase chain reaction and direct sequencing were used to screen DNA samples for DCTN4 variants. A total of 121 adult CF patients from the Cochin Hospital CF centre have been included, all of them carrying two CFTR defects: 103 developed at least 1 pulmonary infection with Pa, and 68 patients of them had CPA. DCTN4 variants were identified in 24% (29/121) CF patients with Pa infection and in only 17% (3/18) CF patients with no Pa infection. Of the patients with CPA, 29% (20/68) had DCTN4 missense variants vs 23% (8/35) in patients without CPA. Interestingly, p.Tyr263Cys tend to be more frequently observed in CF patients with CPA than in patients without CPA (4/68 vs 0/35), and DCTN4 missense variants tend to be more frequent in male CF patients with CPA bearing two class II mutations than in male CF patients without CPA bearing two class II mutations (P = 0.06). Our observations reinforce that DCTN4 missense variants, especially p.Tyr263Cys, may be involved in the pathogenesis of CPA in male CF.
25763772	0	5	DCTN4	T103	UMLS:C4308010
25763772	23	63	chronic Pseudomonas aeruginosa infection	T038	UMLS:C0854135
25763772	67	82	cystic fibrosis	T038	UMLS:C0010674
25763772	83	120	Pseudomonas aeruginosa (Pa) infection	T038	UMLS:C0854135
25763772	124	139	cystic fibrosis	T038	UMLS:C0010674
25763772	141	143	CF	T038	UMLS:C0010674
25763772	189	206	pulmonary disease	T038	UMLS:C0024115
25763772	233	253	chronic Pa infection	T038	UMLS:C0854135
25763772	255	258	CPA	T038	UMLS:C0854135
25763772	302	329	faster rate of lung decline	T033	UMLS:C3160731
25763772	350	363	exacerbations	T033	UMLS:C4086268
25763772	395	411	exome sequencing	T062	UMLS:C3640077
25763772	469	477	isoforms	T103	UMLS:C0597298
25763772	481	491	dynactin 4	T103	UMLS:C4308010
25763772	493	498	DCTN4	T103	UMLS:C4308010
25763772	514	526	Pa infection	T038	UMLS:C0854135
25763772	530	532	CF	T038	UMLS:C0010674
25763772	551	570	respiratory disease	T038	UMLS:C0035204
25763772	592	597	study	T062	UMLS:C2603343
25763772	629	634	DCTN4	T103	UMLS:C4308010
25763772	644	652	variants	T103	UMLS:C0597298
25763772	656	668	Pa infection	T038	UMLS:C0854135
25763772	693	705	Pa infection	T038	UMLS:C0854135
25763772	710	730	chronic Pa infection	T038	UMLS:C0854135
25763772	746	752	cohort	T098	UMLS:C0599755
25763772	762	764	CF	T038	UMLS:C0010674
25763772	788	794	centre	T092	UMLS:C0475309
25763772	796	821	Polymerase chain reaction	T062	UMLS:C0032520
25763772	826	843	direct sequencing	T062	UMLS:C3899368
25763772	864	875	DNA samples	T017	UMLS:C0444245
25763772	880	885	DCTN4	T103	UMLS:C4308010
25763772	886	894	variants	T103	UMLS:C0597298
25763772	917	919	CF	T038	UMLS:C0010674
25763772	938	963	Cochin Hospital CF centre	T092	UMLS:C0019994
25763772	1009	1013	CFTR	T017	UMLS:C1413365
25763772	1048	1067	pulmonary infection	T038	UMLS:C0876973
25763772	1073	1075	Pa	T007	UMLS:C0033809
25763772	1105	1108	CPA	T038	UMLS:C0854135
25763772	1110	1115	DCTN4	T103	UMLS:C4308010
25763772	1116	1124	variants	T103	UMLS:C0597298
25763772	1157	1159	CF	T038	UMLS:C0010674
25763772	1174	1186	Pa infection	T038	UMLS:C0854135
25763772	1210	1212	CF	T038	UMLS:C0010674
25763772	1230	1242	Pa infection	T038	UMLS:C0854135
25763772	1265	1268	CPA	T038	UMLS:C0854135
25763772	1286	1291	DCTN4	T103	UMLS:C4308010
25763772	1301	1309	variants	T103	UMLS:C0597298
25763772	1344	1347	CPA	T038	UMLS:C0854135
25763772	1364	1375	p.Tyr263Cys	T103	UMLS:C0597298
25763772	1415	1417	CF	T038	UMLS:C0010674
25763772	1432	1435	CPA	T038	UMLS:C0854135
25763772	1461	1464	CPA	T038	UMLS:C0854135
25763772	1485	1490	DCTN4	T103	UMLS:C4308010
25763772	1500	1508	variants	T103	UMLS:C0597298
25763772	1542	1544	CF	T038	UMLS:C0010674
25763772	1559	1562	CPA	T038	UMLS:C0854135
25763772	1575	1593	class II mutations	T038	UMLS:C0026882
25763772	1607	1609	CF	T038	UMLS:C0010674
25763772	1627	1630	CPA	T038	UMLS:C0854135
25763772	1643	1661	class II mutations	T038	UMLS:C0026882
25763772	1706	1711	DCTN4	T103	UMLS:C4308010
25763772	1721	1729	variants	T103	UMLS:C0597298
25763772	1742	1753	p.Tyr263Cys	T103	UMLS:C0597298
25763772	1778	1790	pathogenesis	T038	UMLS:C0699748
25763772	1794	1797	CPA	T038	UMLS:C0854135
25763772	1806	1808	CF	T038	UMLS:C0010674